Aarhus University Seal / Aarhus Universitets segl

ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. / Wollenberg, A; Oranje, A; Deleuran, M; Simon, D; Szalai, Z; Kunz, B; Svensson, A; Barbarot, S; von Kobyletzki, L; Taieb, A; de Bruin-Weller, M; Werfel, T; Trzeciak, M; Vestergaard, Christian; Ring, J; Darsow, U; European Task Force on Atopic Dermatitis/EADV Eczema Task Force.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 30, No. 5, 05.2016, p. 729-47.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Wollenberg, A, Oranje, A, Deleuran, M, Simon, D, Szalai, Z, Kunz, B, Svensson, A, Barbarot, S, von Kobyletzki, L, Taieb, A, de Bruin-Weller, M, Werfel, T, Trzeciak, M, Vestergaard, C, Ring, J, Darsow, U & European Task Force on Atopic Dermatitis/EADV Eczema Task Force 2016, 'ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients', Journal of the European Academy of Dermatology and Venereology, vol. 30, no. 5, pp. 729-47. https://doi.org/10.1111/jdv.13599

APA

Wollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., von Kobyletzki, L., Taieb, A., de Bruin-Weller, M., Werfel, T., Trzeciak, M., Vestergaard, C., Ring, J., Darsow, U., & European Task Force on Atopic Dermatitis/EADV Eczema Task Force (2016). ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. Journal of the European Academy of Dermatology and Venereology, 30(5), 729-47. https://doi.org/10.1111/jdv.13599

CBE

Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, Svensson A, Barbarot S, von Kobyletzki L, Taieb A, de Bruin-Weller M, Werfel T, Trzeciak M, Vestergaard C, Ring J, Darsow U, European Task Force on Atopic Dermatitis/EADV Eczema Task Force. 2016. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. Journal of the European Academy of Dermatology and Venereology. 30(5):729-47. https://doi.org/10.1111/jdv.13599

MLA

Vancouver

Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. Journal of the European Academy of Dermatology and Venereology. 2016 May;30(5):729-47. https://doi.org/10.1111/jdv.13599

Author

Wollenberg, A ; Oranje, A ; Deleuran, M ; Simon, D ; Szalai, Z ; Kunz, B ; Svensson, A ; Barbarot, S ; von Kobyletzki, L ; Taieb, A ; de Bruin-Weller, M ; Werfel, T ; Trzeciak, M ; Vestergaard, Christian ; Ring, J ; Darsow, U ; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. / ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. In: Journal of the European Academy of Dermatology and Venereology. 2016 ; Vol. 30, No. 5. pp. 729-47.

Bibtex

@article{4e74d14630024180810621cf0b4346f1,
title = "ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients",
abstract = "Atopic dermatitis (AD) is a clinically defined, highly pruritic, chronic inflammatory skin disease of children and adults. The diagnosis is made using evaluated clinical criteria. Disease activity is best measured with a composite score assessing both objective signs and subjective symptoms, such as SCORAD. The management of AD must consider the clinical and pathogenic variabilities of the disease and also target flare prevention. Basic therapy includes hydrating topical treatment, as well as avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment of visible skin lesions is based on topical glucocorticosteroids and the topical calcineurin inhibitors tacrolimus and pimecrolimus. Topical calcineurin inhibitors are preferred in sensitive locations. Tacrolimus and mid-potent steroids are proven for proactive therapy, which is long-term intermittent anti-inflammatory therapy of the frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is indicated for severe refractory cases. Biologicals targeting key mechanisms of the atopic immune response are promising emerging treatment options. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) may diminish pruritus, but do not have sufficient effect on lesions. Adjuvant therapy includes UV irradiation, preferably UVA1 or narrow-band UVB 311 nm. Dietary recommendations should be patient specific and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. 'Eczema school' educational programmes have been proven to be helpful for children and adults.",
author = "A Wollenberg and A Oranje and M Deleuran and D Simon and Z Szalai and B Kunz and A Svensson and S Barbarot and {von Kobyletzki}, L and A Taieb and {de Bruin-Weller}, M and T Werfel and M Trzeciak and Christian Vestergaard and J Ring and U Darsow and {European Task Force on Atopic Dermatitis/EADV Eczema Task Force}",
note = "{\textcopyright} 2016 European Academy of Dermatology and Venereology.",
year = "2016",
month = may,
doi = "10.1111/jdv.13599",
language = "English",
volume = "30",
pages = "729--47",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients

AU - Wollenberg, A

AU - Oranje, A

AU - Deleuran, M

AU - Simon, D

AU - Szalai, Z

AU - Kunz, B

AU - Svensson, A

AU - Barbarot, S

AU - von Kobyletzki, L

AU - Taieb, A

AU - de Bruin-Weller, M

AU - Werfel, T

AU - Trzeciak, M

AU - Vestergaard, Christian

AU - Ring, J

AU - Darsow, U

AU - European Task Force on Atopic Dermatitis/EADV Eczema Task Force

N1 - © 2016 European Academy of Dermatology and Venereology.

PY - 2016/5

Y1 - 2016/5

N2 - Atopic dermatitis (AD) is a clinically defined, highly pruritic, chronic inflammatory skin disease of children and adults. The diagnosis is made using evaluated clinical criteria. Disease activity is best measured with a composite score assessing both objective signs and subjective symptoms, such as SCORAD. The management of AD must consider the clinical and pathogenic variabilities of the disease and also target flare prevention. Basic therapy includes hydrating topical treatment, as well as avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment of visible skin lesions is based on topical glucocorticosteroids and the topical calcineurin inhibitors tacrolimus and pimecrolimus. Topical calcineurin inhibitors are preferred in sensitive locations. Tacrolimus and mid-potent steroids are proven for proactive therapy, which is long-term intermittent anti-inflammatory therapy of the frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is indicated for severe refractory cases. Biologicals targeting key mechanisms of the atopic immune response are promising emerging treatment options. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) may diminish pruritus, but do not have sufficient effect on lesions. Adjuvant therapy includes UV irradiation, preferably UVA1 or narrow-band UVB 311 nm. Dietary recommendations should be patient specific and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. 'Eczema school' educational programmes have been proven to be helpful for children and adults.

AB - Atopic dermatitis (AD) is a clinically defined, highly pruritic, chronic inflammatory skin disease of children and adults. The diagnosis is made using evaluated clinical criteria. Disease activity is best measured with a composite score assessing both objective signs and subjective symptoms, such as SCORAD. The management of AD must consider the clinical and pathogenic variabilities of the disease and also target flare prevention. Basic therapy includes hydrating topical treatment, as well as avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment of visible skin lesions is based on topical glucocorticosteroids and the topical calcineurin inhibitors tacrolimus and pimecrolimus. Topical calcineurin inhibitors are preferred in sensitive locations. Tacrolimus and mid-potent steroids are proven for proactive therapy, which is long-term intermittent anti-inflammatory therapy of the frequently relapsing skin areas. Systemic anti-inflammatory or immunosuppressive treatment is indicated for severe refractory cases. Biologicals targeting key mechanisms of the atopic immune response are promising emerging treatment options. Microbial colonization and superinfection may induce disease exacerbation and can justify additional antimicrobial treatment. Systemic antihistamines (H1R-blockers) may diminish pruritus, but do not have sufficient effect on lesions. Adjuvant therapy includes UV irradiation, preferably UVA1 or narrow-band UVB 311 nm. Dietary recommendations should be patient specific and elimination diets should only be advised in case of proven food allergy. Allergen-specific immunotherapy to aeroallergens may be useful in selected cases. Psychosomatic counselling is recommended to address stress-induced exacerbations. 'Eczema school' educational programmes have been proven to be helpful for children and adults.

U2 - 10.1111/jdv.13599

DO - 10.1111/jdv.13599

M3 - Journal article

C2 - 27004560

VL - 30

SP - 729

EP - 747

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 5

ER -